[Effects comparison of lamivudine therapy for hepatitis B virus genotypes B and C].
OBJECTIVE
To determine the lamivudine response of HBV genotypes in patients with HBV DNA positive chronic hepatitis.


METHODS
Clinical data from 235 patients in the original trial were analyzed.


RESULTS
135 patients received lamivudine and 100 patients as controls. Almost all patients had HBV genotypes B or C. Antiviral response were 92.9% and 75.9% in lamivudine-treated patients (chi-square = 6.628, P < 0.05) and 9.8% and 8.5% in untreated controls (P > 0.05) with HBV genotype B and C, respectively. The incidences of lamivudine-induced mutation in YMDD motif were 3.6% and 16.5% in HBV genotype B and C, respectively (chi-square = 5.508, P < 0.01). We identified HBV genotype B, elevated pretreatment alanine aminotransferase (ALT) levels, and low pretreatment HBV DNA levels as independent factors associated with antiviral response.


CONCLUSIONS
HBV genotype B was associated with a higher rate of lamivudine-induced HBV DNA clearance and lower rate of lamivudine-induced YMDD mutation compared with genotype C. HBV genotypes may be an important determinant of lamivudine therapy of chronic hepatitis B.
Zhou
Jian-liang
JL
Department of Infectious Diseases, Shenzhen People's Hospital, Jinan University Medical School, Shenzhen 518020, China.
Wu
Shi-pin
SP
D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D004279:DNA, Viral / Q000097:blood; D005260:Female; D015684:Gene Products, pol / Q000235:genetics; D005838:Genotype; D006515:Hepatitis B virus / Q000145:classification* / Q000235:genetics; D019694:Hepatitis B, Chronic / Q000188:drug therapy*; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use*; D008297:Male; D009154:Mutation
D000998:Antiviral Agents; D004279:DNA, Viral; D015684:Gene Products, pol; C066027:P protein, Hepatitis B virus; D019259:Lamivudine